Related Experiment Video
Updated: Jan 20, 2026

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples
Published on: March 14, 2014
Harnessing T-cell activity against prostate cancer: A therapeutic microparticulate oral cancer vaccine
Ashwin C Parenky1, Archana Akalkotkar2, Nihal S Mulla3
1Mercer University, Vaccine Nanotechnology Laboratory, Center for Drug Delivery Research, Atlanta, GA 30341, USA.
Abstract:
Prostate Cancer specific immunotherapy in combination with immune stimulating adjuvants may serve as a viable strategy for facilitating tumor regression and preventing recurrence. In this study, an oral microparticulate vaccine encapsulating tumor associated antigens (TAA) extracted from a murine prostate cancer cell line, TRAMP-C2, was formulated with the help of a spray dryer. Microparticles were characterized in vitro to determine their physicochemical properties and antigenicity. Formulated microparticles had an average size of 4.92 ± 0.5 μm with a zeta potential of 7.92 ± 1.2 mV. In order to test our formulation for its ability to demonstrate adequate antigen presentation and co-stimulation, microparticles were tested in vitro on murine dendritic cells. In vitro biological characterization demonstrated the activation of specific immune system markers such as CD80/86, CD40, MHC-I and MHC-II. Following in vitro characterization, in vivo anti-tumor efficacy of the oral microparticulate vaccine was evaluated in C57BL/6 male mice. Combination therapy of vaccine microparticles with cyclophosphamide and granulocyte macrophage-colony stimulating factor (GM-CSF) demonstrated a five-fold reduction in tumor volume as compared to non-vaccinated mice. At the cellular level, cyclophosphamide and GM-CSF augmented the vaccine response as indicated by the reduced tumor volume and significant elevation of cytotoxic T-cell (CTL) CD8+ and (T-helper) CD4+ T-cells compared to mice receiving vaccine microparticles alone. Furthermore, our studies indicate a significant reduction in T-regulatory cells (T-regs) in mice receiving vaccine along with GM-CSF and cyclophosphamide, one of the immune escape mechanisms linked to tumor growth and progression. Thus, oral microparticulate vaccines have the potential to trigger a robust anti-tumor cellular response, and in combination with clinically relevant agents, significantly resist tumor growth and progression.
Insights
An oral microparticulate vaccine targeting prostate cancer antigens, when combined with cyclophosphamide and GM-CSF, significantly reduced tumor volume in mice. This combination therapy also boosted anti-tumor T-cells and decreased immune-suppressing T-regulatory cells.
Area of Science:
- Immunology
- Oncology
- Materials Science
Background:
- Prostate cancer immunotherapy requires strategies to enhance tumor regression and prevent recurrence.
- Tumor-associated antigens (TAA) are key targets for cancer vaccines.
- Immune stimulating adjuvants can potentiate vaccine efficacy.
Purpose of the Study:
- To formulate and characterize an oral microparticulate vaccine encapsulating prostate cancer TAA.
- To evaluate the in vitro immune-stimulating potential of the microparticle vaccine.
- To assess the in vivo anti-tumor efficacy of the vaccine in combination therapy.
Main Methods:
- Spray-dried microparticles encapsulating TRAMP-C2 derived TAA were formulated.
- In vitro characterization included size, zeta potential, and immune cell marker analysis (CD80/86, CD40, MHC-I/II) on dendritic cells.
- In vivo studies involved administering the vaccine with cyclophosphamide and GM-CSF to C57BL/6 mice and measuring tumor volume and T-cell populations.
Main Results:
- Microparticles exhibited optimal physicochemical properties (4.92 μm size, 7.92 mV zeta potential) and induced dendritic cell activation.
- Combination therapy with cyclophosphamide and GM-CSF resulted in a five-fold reduction in tumor volume compared to controls.
- Significant increases in cytotoxic T-cells (CD8+) and T-helper cells (CD4+), alongside a decrease in T-regulatory cells, were observed.
Conclusions:
- Oral microparticulate vaccines effectively deliver prostate cancer antigens and stimulate an anti-tumor immune response.
- Combination therapy with cyclophosphamide and GM-CSF enhances vaccine efficacy, reducing tumor growth and modulating the tumor microenvironment.
- This approach shows promise for overcoming immune evasion mechanisms in prostate cancer.
Related Concept Videos
07:16Isolation of Cancer Stem Cells From Human Prostate Cancer Samples
05:07Intra-prostatic Injection of Cancer Cells: A Technique to Deliver Cancer Cells for Establishing Orthotopic Prostate Cancer Mouse Model
06:48An Orthotopic Murine Model of Human Prostate Cancer Metastasis
05:19A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
08:03Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells
08:54Generation of Tumor Organoids from Genetically Engineered Mouse Models of Prostate Cancer

